TSNI SEC Suspension because of questions regarding the adequacy and accuracy of information about the company.

https://www.sec.gov/litigation/suspensions/2021/34-91170.pdf

Order:

https://www.sec.gov/litigation/suspensions/2021/34-91170-o.pdf

TSNI is severely delinquent in filing the company's Financials. The stock is at risk of an SEC Suspension and subsequent stock registration revocation.

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001398026&owner=exclude&count=40&hidefilings=0

What's the status on this company?
I have not heard anything for a year.

Nothing there to begin with. Grant junkie on steroids. Trying to discover how many ways the FDA tell a company NO while blowing through investor dinero? Cash is gone now. Nothing remains.

Cancer detection company with cancer they couldn't get rid of.

Zero. Nobody home. Empty shell within a shell.

Nice move here today.

Where are we headed? is the company done diluting?

That would be the $64,000 Question :)

Where is the bottom on this?

Got in today for the long haul. Good luck to all!

This appears almost identical to the "system" touted by IMDS.

Any thoughts on if either one may eventually win approval?

And Still Broke.. Post R/S with the prices way back down now it sure seems to look like a great time to accumulate some shares if any will let loose at these bid prices ...

You called that shorting candidate like a Pro...

TechniScan Elects Joe Pepper, Ph.D. as Chairman of the Board


SALT LAKE CITY (December 15, 2010) -- TechniScan (OTC Bulletin Board: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, announced that Joe Pepper, Ph.D. has been elected as chairman of the board of directors of TechniScan.

“As a member of the current board of directors, Joe Pepper has already made significant contributions in helping us bring TechniScan's Warm Bath Ultrasound closer to commercialization, and his leadership and experience in the field will further benefit the company as he takes over as the chairman," said outgoing Board Chairman Ken Hungerford.
Hungerford has served as chairman since the company went public in the fall of 2009, and he will continue to serve on the board’s executive committee along with Pepper and TechniScan CEO David Robinson.

With 28 years in the medical device field, Pepper currently serves as a consultant to medical device start-ups. Formerly he served as CEO of U-Systems, Inc., a privately-backed start-up that developed automated ultrasound for the early detection of breast cancer in women with dense breast tissue. He was CEO for OEC Medical Systems, a NYSE-traded, mobile fluoroscopic imaging equipment manufacturer until it was sold to GE Healthcare. He spent 15 years with The BOC Group, Plc., where he served as president of its subsidiary Ohmeda Medical Devices, which was responsible for international selling and distribution of medical devices, and as president of Ohmeda Medical Equipment.

Pepper has been a member of TechniScan’s board of directors since October 2009. He has a BS/MS in Engineering Science from Florida State University, a Ph.D. in Mechanical Engineering from Stanford University and an MBA from The Harvard Business School.

"I am excited about the opportunity to add my knowledge and perspective to TechniScan, a company I have admired for quite some time. Its 3D ultrasound images have impressive specificity and the potential to change the way that radiologists and oncologists detect cancer in the breast. The TechniScan management team has outstanding depth and diversity of perspective. I am honored to be a part of the group, and I feel confident that with our collective experience, we can make TechniScan’s imaging modality the premier method for breast diagnostics,” said Pepper.

“It’s a pleasure to be working with a person of Joe’s professional caliber and look forward to working to effectively execute our business plan with him,” Robinson said.

TechniScan and its 3D breast ultrasound technology , will be featured at 2010 Southern California Investors Conference


SALT LAKE CITY (August 16, 2010) – TechniScan (OTC BB: TSNI), the developer of a novel warm bath, 3D breast diagnostic imaging system today announced that it will be a presenter at the 2010 Southern California Investor Conference.

Dave Robinson, chief executive officer for TechniScan will be presenting a market overview for breast imaging, the unique attribute’s of TechniScan’s Warm Bath Ultrasound system, and the company’s strategy to take the product to the commercial medical market.

In its 15th year, the Southern California Investor Conference highlights the wealth of growth companies located in the Southern California region including world recognized life science, technology, media and real estate/financial companies. Officers from 30 of Southern California's leading companies will present corporate updates and business insights to the investment community.

The conference is being held at the Island Hotel in Newport Beach on Tuesday, August 17. TechniScan will be presenting in Cabana room 4 at 2 pm WDT.

good luck. you ll need it

Yeah , this is killing me ... i'm broke : (

Have only been able to short 1000 shares so far but I'm up over $1000 so far. Will short to 10 cents. TOXIC CONVERT IN PLACE> SHORT AT WILL.

PROMOTERS WILL BE TRYING TO DUMP SHARES SHORTLY>

BUYER BEWARE.

GREAT SHORTING CANDIDATE! TOXIC BOTTOMLESS convertible in place for 1.8 MM. Conversion due in September. What a GREAT shorting opportunity. With no news on the FDA front the arb hedge funds will take this down on no volume. Caveat Emptor.

TechniScan’s warm bath 3D breast imaging device featured as top emerging medical technology


CEO says the demand for breast diagnostics will grow with aging baby boomers
SALT LAKE CITY (August 11, 2010) – TechniScan (OTC BB: TSNI), was among the 25 top emerging medical technology companies featured today on Life Science Intelligence’s (LSI) investor presentation.
This online venue provides a timely release of the most promising emerging medical technology companies identified by LSI. The event provides detailed information on a select group of companies, including presentations (audio and slides), executive summaries, fund raising status, partnering status, and much more.
“This presentation places TechniScan and our warm bath, 3D breast imaging device among some of the most promising private and public medical technology companies today. It is a comprehensive and informative venue for investors to evaluate the latest technologies that have the potential to change the future of medicine,” said Dave Robinson, chief executive officer for TechniScan.
TechniScan’s warm bath, 3D breast imaging device is designed to capture three-dimensional images of the breast as a woman lies prone on a table and state-of-the-art ultrasound technology is used in a warm water tank to image the breast anatomy. Its revolutionary new method of imaging produces information and whole breast images that are not available with traditional reflection ultrasound or whole breast ultrasound systems presently on the market.
With the aging baby boomer population, the market segment for breast screening and diagnostic devices is expected to grow by 1.5 percent each year over the next twenty years. According to the National Cancer Institute, the highest percentage of breast cancer is found in women over the age of 65.
“Strictly considering the demographic growth projections for breast screening and diagnostics, there is a built in demand for our device. Couple this with the desire from women and radiologists for comfortable and more sophisticated tools to more accurately diagnose breast cancer, and we are very confident in the demand for our 3D breast imaging system,” said Robinson.
Unique to the ultrasound market, TechniScan’s revolutionary science employs transmission ultrasound in addition to standard reflection ultrasound to form its high-resolution, compounded 360-degree view of the breast in a natural uncompressed condition. The technology in protected by multiple patents.
Life Science Intelligence (LSI) delivers high quality market data and information to medical technology executives, entrepreneurs and investors. LSI produces its own information products and partners with select top tier information companies to distribute their high-end information.
To view today’s investor presentation, go to www.lifescienceintelligence.com and select EMT Spotlight and “register to attend.” The presentations will be archived on the LSI website. You can also call LSI at 1-714-847-3540.

TechniScan, Inc. Announces One-for-Four Reverse Stock Split


Stock Will Begin Trading on a Split-Adjusted Basis on June 28, 2010

SALT LAKE CITY (June 24, 2010) – TechniScan (OTC BB: TSNI), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced it filed a certificate of amendment to implement a one-for-four reverse stock split of the company’s issued and outstanding common stock.

The reverse stock split, which was previously approved by the company’s board of directors and stockholders, will take effect with the opening of the markets on Monday, June 28, 2010, subject to approval by FINRA. Trading of TechniScan’s common stock will continue on a reverse stock split-adjusted basis.

The board believes that the reverse stock split will increase market price, help attract long term investors and increase investor interest. The increase in stock price will also allow the company to meet the requirements to be accepted to the American Stock Exchange (AMEX), should the company pursue an application for such listing.

TechniScan stockholders will receive one new TechniScan share for every four shares that they held prior to the split, and all fractional shares will be rounded up to the next whole share on a certificate basis only. As a result of the reverse stock split, the number of shares of the company’s common stock outstanding will be reduced from approximately $82.9 million to approximately $20.7 million shares.

To indicate that the reverse stock split has occurred, a “D” will be added to the company’s trading symbol, such that the post-split common stock will trade under the symbol “TSNID” beginning on June 28, 2010 for a period of 20 trading days, after which TechniScan’s common stock will resume trading under the symbol “TSNI.” The new CUSIP number for the company’s post-split common stock will be 87855G 206.

TechniScan announces adding another center to worldwide clinical trials for new breast imaging system


Announces preliminary clinical results and evaluations

SALT LAKE CITY (June 16, 2010) – TechniScan, (OTC BB: TSNI) a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, today announced that it has launched a clinical study in Rochester, Minn., its third new clinical site to commence in the last five months.

TechniScan’s Warm Bath Ultrasound (WBU) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table and state-of-the-art ultrasound technology is used in a warm water tank to image the breast anatomy. Its revolutionary new method of imaging produces information and whole breast images that are not available with traditional reflection ultrasound or whole breast ultrasound systems presently on the market.

To date, TechniScan has scanned over 800 women in clinical studies in Salt Lake City and Ogden, Utah as well as Orange and San Diego, California. These past clinical studies focused on key factors like image quality, repeatability, and establishing protocols for testing baseline values for positive and negative predictive capabilities of the system.

According to Dr. John Klock, TechniScan's chief medical officer, the most recently completed clinical work continues to support that refraction-corrected reflection images highlight connective tissue features within the breast, whereas the speed-of-sound images show fibroglandular, ductal and terminal lobular units with high resolution.

Image consistency and reproducibility, whether it is weeks, months or a year between exams, are critical to support precise and reliable assessment of breast lesions. Clinical studies in San Diego recently evaluated the ability of the system to reliably reproduce images from the same woman.

"We have clearly demonstrated that the system can reliably reproduce images based on reflection and sound transmission and that those images will have significant clinical utility," said David Robinson TechniScan's president and CEO.

“Volumetric whole-breast imaging provides a substantial practical advantage over conventional very-small-field-of-view sonography. We are greatly aided by the ability to produce repeatable whole-breast comparisons – left to right and present to past. These comparisons are the nuts and bolts of breast imaging, by any modality,” said Michael Andre, Ph.D., adjunct professor of radiology and director of medical physics at University of California, San Diego School of Medicine.

Building on this prior clinical work, the current clinical studies in Freiberg, Germany, San Diego and Rochester will involve at least 500 women with various types of breast lesions. Major objectives of the 12-month study will be to compare WBU to conventional breast sonography and MRI as well as to examine the WBU system’s ability to differentiate between normal, benign and malignant breast tissue. These clinical studies in the U.S. are funded by a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute.

TechniScan’s current study sites include the University Medical Center Freiburg in Germany, Moores UCSD Cancer Center, and the latest clinical study site in Rochester, Minnesota as well as limited imaging studies that support product development in Genoa, Italy and Salt Lake City, Utah.

“Overall we expect to image another 600 or more patients in our clinical program over the next 6-12 months,” said Robinson. “These studies will provide us with critical information about the clinical utility and application of the WBU capabilities.”

“The feedback that we are receiving from our scientists and radiologists at our study sites gives us good reasons to remain cautiously optimistic,” said Klock.

Researchers involved in the studies will also utilize TechniScan’s groundbreaking imaging network, which provides them with the ability to archive, store, and retrieve WBU images and relevant medical records and to collaborate with other research sites.

“Our vision is to begin to create a database of thousands of breast images as well as the underlying and related image data,” said Robinson. “With complete anonymity, women can contribute their mammograms, breast MRIs and WBU images along with related pathology and other information to provide researchers around the world an unprecedented opportunity to study breast cancer. TechniScan’s imaging network will also allow timely and efficient collaboration of patient’s records for her medical team’s use. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system.”

TechniScan Announces Special Meeting of Stockholders


SALT LAKE CITY (June 9, 2010) -- TechniScan (OTC BB: TSNI) a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, will hold a special meeting of stockholders on Friday, June 18, 2010 at 10:00 a.m. MDT at the company’s offices located at 3216 South Highland Drive, Suite 200, Salt Lake City, Utah 84106.

The purpose of the special meeting is to approve an amendment to the company’s Certificate of Incorporation to effect a 1-for-4 reverse stock split of the issued and outstanding common stock. The number of the company’s authorized shares of common stock will remain 150,000,000 and will not be proportionally reduced.

TechniScan Files Registration Statement for Public Offering of its Equity

SALT LAKE CITY (June 3, 2010) -- TechniScan, Inc. (OTC BB: TSNI) a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a best efforts offering of a minimum of 16,000,000 units and a maximum of 28,500,000 units.

Each unit consists of one share of common stock and one warrant to purchase 0.4 shares of common stock. TechniScan is also registering shares of its common stock for sale by certain selling stockholders (as identified in a separate prospectus) outside of the units offering.

Jesup & Lamont Securities Corp. and Global Hunter Securities LLC will act as placement agents for the units offering but not for the shares of common stock to be sold by the selling stockholders.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be a sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

When available, copies of the preliminary prospectus relating to the offering may be obtained from Jesup & Lamont Securities Corp., 110 East 59th Street - 37th Floor
New York, NY 10022 or by calling Mark Diamond (212) 918-0415.

Patent awarded to the design of TechniScan’s unique 3-D breast imaging system


The novel ultrasound-imaging device could simplify breast biopsy and treatment

SALT LAKE CITY (May 13, 2010) – A newly awarded U.S. Patent will protect TechniScan, Inc’s., (OTC BB: TSNI) novel way to image, biopsy and treat breast cancer.

U.S. Patent 7,699,783 B2 titled “Method for Imaging and Treating a Breast” covers the company’s design of a 3-D, Warm Bath Ultrasound™ system that images while a woman lies prone on a table with her breast comfortably immersed in a warm water, state-of-the art scanning system.

Since she is lying on a table with her breast through an opening, the breast is in a pendant, uncompressed position that allows for a true three-dimensional image to be constructed.

“Imaging of the non-compressed pendant breast, similar to positioning for breast MRI, provides reproducible, 3-D anatomically accurate detail,” said Yuri Parisky, M.D., medical imaging director at Mammoth Hospital in Calif. “It is the ideal position to image the breast.”

A vital element of the new patent is the table design of the Warm Bath Ultrasound™ (WBU™) system, which rises above the water bath tank after the scan. This functionality has three key benefits: The woman remains on the same table for diagnostics and treatment, it maintains the known position of the tumor or lesion and allows the three-dimensional image to be utilized to guide treatment instruments.

“In essence, our WBU system provides a 3-D navigational map of the breast, and this could be useful to breast surgeons, radiologists and oncologists,” said Barry Hanover, chief operating officer at TechniScan and one of the inventors of the system. “The fact that our table can also be raised, with the breast maintained in the same position as during the 3-D image capture, could improve the efficiency and accuracy of biopsies and minimally invasive treatment of cancers.”

The WBU system is radiation-free and produces three unique sets of images that utilize reflection ultrasound, speed of sound and attenuation of sound, resulting in an ultrasound computed tomography image. The goal of the 360-degree, high-resolution images is to provide new diagnostic information to doctors who seek to find cancers when they are smaller and easier to treat.

Recently the proprietary algorithms that gather and process the complex set of data generated in the WBU system were also awarded a patent. The patent will protect the company’s intellectual property and the revolutionary way it utilizes the entire ultrasound spectrum to form its unique images of the breast.

TechniScan secures patent on imaging method for breakthrough 3-D breast ultrasound


Patented methods deliver imaging results within minutes

SALT LAKE CITY (May 6, 2010) – TechniScan, Inc., (OTC BB: TSNI) the developer of a revolutionary 3-D breast imaging system, announced today the grant of U.S. Patent 7,684,846, which provides additional intellectual property protection for proprietary methods in creating diagnostic images from complex wave fields.

The patent titled “Apparatus and Method for Imaging Objects with Wave Fields” outlines how the company’s groundbreaking algorithms are translated into a high resolution, 3-D ultrasound image of the human breast. The patent also includes recursive methods for increasing the speed that the images are processed, which may deliver faster clinical outcomes for women awaiting breast-imaging results.

“This patent is another example of the deep portfolio of unique IP (intellectual property) that has resulted from our 20 years of research in the fields of mathematics and physics. The patent is a result of extensive work by our entire team to extract the benefits of complex transmission wave field imaging methods,” said Dave Robinson, chief executive officer at TechniScan.

The science developed at TechniScan, Inc. has led to new ways of utilizing whole breast ultrasound technology that may more accurately distinguish pathological from normal breast tissue. The images are captured using a comfortable, radiation-free method as a woman lies prone on an examination table and ultrasound is directed, using warm water as a coupling medium, through her breast tissue.

FDA decision would be sweet but still don't know when... It's like "How long is a piece of string" ... I do feel that when it does get approved that it will literally replace Mammograms that most women should have done annually and well , lets see , how many women are in the USA that are between the ages of say 30 to still breathing .. Man that would be a lot of revenue... especially given the choice to have things checked out "Non-intrusively" vs/ "hurt like hell" which makes a lot of them put their checks off into years between instead of yearly .. Hopefully the FDA decision will be quicker on this than some form of drug that needs testing for years .. And since it doesn't take "Highly trained personnel" to do the procedure it may fit in with the newer health care plan budgets... Hopefully...

yo dude you in this for the FDA decision ?

Innovation in mathematics leads to revolutionary breast-imaging system


TechniScan’s scientific breakthrough in Inverse Scattering presented to doctors and scientists at AIUM conference

SALT LAKE CITY (April 7, 2010) – The groundbreaking algorithms developed at TechniScan, Inc. (OTC BB: TSNI) have led to a new arena of whole breast ultrasound technology, as presented at a national medical ultrasound conference in San Diego in March.

TechniScan cofounder and scientist-mathematician, James Wiskin, Ph.D. spoke at the American Institute of Ultrasound Medicine (AIUM) conference held at the San Diego Marriott Hotel and Marina about the unique methods in which the company’s 3-dimensional whole breast ultrasound captures anatomical images of the breast.

The breakthrough in imaging is a result of Wiskin’s and colleagues David Borup, Ph.D., and Steven Johnson’s, Ph.D. work in the mathematics of inverse scattering. TechniScan’s Warm Bath Ultrasound™ (WBU) system uses a unique combination of traditional B-mode (reflective) ultrasound and two types of transmission ultrasound – speed of sound and attenuation of sound, to produce three unique sets of images.

“This revolutionary new method of imaging produces information not available with traditional reflection ultrasound or whole breast ultrasound as it is presently being developed. Uniquely, we can also capture 360 degree compounded coronal images,” said Wiskin.

The goal of the new technology is to improve breast imaging and provide tissue characterization that will more accurately distinguish pathological from normal breast tissue. The images are captured in a comfortable, radiation-free method as a woman lies prone on an examination table and ultrasound is directed, using warm water as a coupling medium, into the patient’s breast tissue.

“Our quantitative, high-resolution, speed of sound and attenuation estimates are unique to whole breast ultrasound and have the potential to deliver new diagnostic tools to radiologist. There are many possible applications for our technology and we are looking forward to collaborating with the medical community and breast research centers internationally,” said Wiskin.

Wiskin is a co-inventor of the fundamental imaging algorithms used by TechniScan to produce whole breast ultrasound images. His research includes inverse scattering theory, image processing, and acoustic, electromagnetic, and elastic wave propagation. His dissertation at the University of Utah (mathematics) established new inverse scattering imaging methods. He currently holds a faculty position in the Department of Bioengineering at the University of Utah.

TechniScan Closes Bridge Financing


Provides Additional Growth and R&D Capital
Biotex Pharma Investments LLC Lead Investor with Participation from TechniScan Directors and Shareholders

SALT LAKE CITY (April 5, 2010) -- TechniScan, Inc.’s (OTC BB: TSNI) a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it had closed the first $1.85 million of a proposed $2.5 million bridge financing, structured as convertible debt, with accredited investors.

Biotex Pharma Investments LLC served as the lead investor and additional participation came from TechniScan directors and shareholders. Jesup & Lamont Securities Corp. served as the placement agent for the transaction.

”We are pleased to secure this additional capital, enabling us to continue our growth and development plans,” commented David Robinson, TechniScan’s chief executive officer.

Mark Diamond, managing director Investment Banking at Jesup & Lamont, added, “TechniScan represents an exciting company poised to bring a significant technological advancement to the problems of diagnosing breast cancer early and accurately. The company’s innovative technology and deep management team was instrumental in quickly bringing together high quality, accredited investors to complete this transaction.”

What's happening with this company? Anyone know? Seems like they have a good product and all the SEC filings in order. Just curious wha there game plan is for the year.

Thanks

TechniScan teams with researchers at UC San Diego in clinical study with Warm Bath UltrasoundTM system


SALT LAKE CITY (March 9, 2010) -- TechniScan, Inc. (OTC BB: TSNI) (“TechniScan” or the “Company”), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it has commenced phase two of its grant study at the University of California, San Diego (UCSD) Moores Cancer Center.

TechniScan’s Warm Bath Ultrasound (WBU™) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table and state-of-the- art ultrasound technology is used in a warm water tank to capture images of the breast anatomy.

The Moores UCSD Cancer Center is a National Cancer Institute (NCI) designated comprehensive cancer center with scientists and clinicians focused on developing the next generation of cancer therapies and cures. The TechniScan Warm Bath UltrasoundTM system investigations will be conducted with Michael P. Andre, Ph.D., Professor of Radiology, and breast radiologists Dr. Linda Olson and Dr. Haydee Ojeda-Fournier.

Funded by a NCI Small Business Innovation Research Grant (SBIR) from the National Institute of Health, the study will involve approximately 130 women with various types of breast lesions. Major objectives of the 12-month study will be to compare WBU TM to conventional breast sonography and to examine the WBU TM system’s ability to differentiate between normal, benign and malignant breast tissue.

“We are excited to begin this new phase in the development of WBU TM; it marks a genuine milestone in which our work may be translated to the front lines of the clinical world, ” said Andre.

Researchers involved in the study will also utilize TechniScan’s groundbreaking imaging network, which provides them with the ability to archive, store, and retrieve WBU TM images and relevant medical records and to collaborate with other researchers at sites in Freiburg, Germany, Salt Lake City and Rochester, Minnesota.

“Our vision is to begin to create a database of thousands of breast images and related data,” said Dave Robinson, chief executive officer at TechniScan, Inc. “With complete anonymity, women may contribute their mammograms, breast MRI’s and WBU TM images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. TechniScan’s imaging network will also allow timely and efficient collaboration of patient’s records for her medical team’s use. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system.”

TechniScan launches clinical study to assess clinical utility of Warm Bath Ultrasound
3. March 2010 01:07

TechniScan, Inc. (OTC Bulletin Board: TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated 3-D breast ultrasound imaging system, today announced that in collaboration with University Medical Center Freiburg in Germany, it has launched a clinical study to assess clinical utility of TechniScan's Warm Bath Ultrasound.

TechniScan's Warm Bath Ultrasound (WBU™) system is designed for state-of-the-art ultrasound technology, used in a warm water tank, to capture 3-D images of the breast as a woman lies prone on a table.

The University Medical Center Freiburg was founded in 1457 and is one of the most prestigious and reputable hospitals in Europe due to its extensive clinical capabilities and advances in medical research. The Breast Examination Center of the Radiology Department, University Medical Center Freiburg is a regional center for women's health and it is the ideal place for the study.

Clinicians will scan a total of at least 150 women within three defined groups: Those with normal mammography findings, those with known benign lesions, and those with known malignancies. The study includes direct comparison of TechniScan's WBU™ images against mammogram, MRI and hand held ultrasound to directly evaluate the ability of WBU™ in providing comparative diagnostic findings.

Italian medical imaging company Esaote cooperated with TechniScan in the development of the WBU™ system and will support TechniScan's efforts in Europe and in Italy. "The Warm Bath Ultrasound system has been developed with groundbreaking science and technology," said Dr. Luigi Satragno, R&D and strategic marketing general manager of Esaote. "We look forward to seeing the clinical studies results and to a long and productive partnership with TechniScan."

Radiologists involved in the Freiburg study will utilize TechniScan's imaging network which provides them with the ability to archive, store, and retrieve anonymous WBU™ images and relevant medical records and will discuss and compare their results with other researchers.

"Our vision is to begin to create a database of thousands of anonymous breast images and related data," said Dave Robinson, chief executive officer at TechniScan, Inc. "This scientific database will consist of anonymous mammograms, breast MRIs and WBU™ images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system."

SOURCE TechniScan, Inc.

TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg UniversityLast update: 3/2/2010 8:00:00 AMSALT LAKE CITY, March 2, 2010 /PRNewswire via COMTEX/ -- TechniScan, Inc. (TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated 3-D breast ultrasound imaging system, today announced that in collaboration with University Medical Center Freiburg in Germany, it has launched a clinical study to assess clinical utility of TechniScan's Warm Bath Ultrasound. TechniScan's Warm Bath Ultrasound (WBU(TM)) system is designed for state-of-the-art ultrasound technology, used in a warm water tank, to capture 3-D images of the breast as a woman lies prone on a table. The University Medical Center Freiburg was founded in 1457 and is one of the most prestigious and reputable hospitals in Europe due to its extensive clinical capabilities and advances in medical research. The Breast Examination Center of the Radiology Department, University Medical Center Freiburg is a regional center for women's health and it is the ideal place for the study. Clinicians will scan a total of at least 150 women within three defined groups: Those with normal mammography findings, those with known benign lesions, and those with known malignancies. The study includes direct comparison of TechniScan's WBU(TM) images against mammogram, MRI and hand held ultrasound to directly evaluate the ability of WBU(TM) in providing comparative diagnostic findings. Italian medical imaging company Esaote cooperated with TechniScan in the development of the WBU(TM) system and will support TechniScan's efforts in Europe and in Italy. "The Warm Bath Ultrasound system has been developed with groundbreaking science and technology," said Dr. Luigi Satragno, R&D and strategic marketing general manager of Esaote. "We look forward to seeing the clinical studies results and to a long and productive partnership with TechniScan." Radiologists involved in the Freiburg study will utilize TechniScan's imaging network which provides them with the ability to archive, store, and retrieve anonymous WBU(TM) images and relevant medical records and will discuss and compare their results with other researchers. "Our vision is to begin to create a database of thousands of anonymous breast images and related data," said Dave Robinson, chief executive officer at TechniScan, Inc. "This scientific database will consist of anonymous mammograms, breast MRIs and WBU(TM) images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system." About Esaote Esaote is one of the fastest growing medical imaging companies in the world specializing in high performance ultrasound systems and is a key investor in TechniScan, Inc. Esaote's premium hand held ultrasound system, the MyLab 70 XVG, is integrated into TechniScan's Warm Bath Ultrasound system to provide both automated reflection imaging and to aid in hand-guided breast biopsy. As the key OEM supplier for the WBU(TM) system, Esaote provides TechniScan with support for engineering, regulatory and manufacturing initiatives.

TechniScan cofounder to speak@ SPIE Medical Imaging Conference

TechniScan cofounder to speak at SPIE Medical Imaging Conference about ground-breaking science behind the company’s ultrasound technology

SALT LAKE CITY, UTAH (February 10, 2010) -- TechniScan, Inc.’s (OTC BB: TSNI) cofounder and scientist-mathematician, James Wiskin, Ph.D, will be a presenting speaker at the SPIE Medical Imaging Conference in San Diego this weekend.

The TechniScan Warm Bath Ultra Sound (WBU TM) system, capable of 3-dimensional whole breast imaging, is a result of Wiskin’s and colleague David Borup’s, Ph. D., groundbreaking work in the mathematics of inverse scattering. Wiskin will be presenting “Inverse Scattering and Refraction Corrected Reflection for Breast Imaging” to attendees of the SPIE conference at the Town and Country Resort & Convention Center.

SPIE (http://spie.org/) is a non-profit international society for the exchange, collection and dissemination of knowledge in optics, photonics and imaging engineering. SPIE organizes conferences, courses and exhibitions covering many aspects and applications of modern technology.

“The WBU system is the culmination of many years of concentrated effort. We are pleased to present our state-of-the-art technology and scientific development to such a distinguished group,” said David Robinson, the company’s chief executive officer.

Wiskin is a cofounder and co-inventor of the fundamental imaging algorithms used by TechniScan to produce whole breast ultrasound images. His research includes inverse scattering theory, image processing; and acoustic, electromagnetic, and elastic wave propagation. His dissertation at the University of Utah (Mathematics) established new inverse scattering imaging methods. He currently holds a faculty position in the Department of Bioengineering at the University of Utah, where he has taught upper division courses since 1991.

TechniScan Inc. Selects Sun Microsystems' Java CAPS to Develop Integrated Healthcare Services

Service-Oriented Architecture Approach Connects Systems to TechniScan's Datacenter and Shares Patient Data Across Organizations

SANTA CLARA, Calif. January 6, 2010 Sun Microsystems, Inc. (NASDAQ: JAVA) today announced that it will design a Sun Service-Oriented Architecture (SOA) solution architecture based on Sun's Java Composite Application Platform Suite (CAPS) and provide expert implementation services for TechniScan, Inc., a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system called SVARA. Using Sun's Java CAPS, TechniScan should be able to bring its SVARA Ultrasound technology to market faster - potentially improving the way breast cancer is diagnosed and treated. For more information on Sun Java CAPS, go to http://www.sun.com/software/javaenterprisesystem/javacaps/index.jsp.

"Sun has a long history of helping to solve the integration challenges facing healthcare payers and providers around the world, consistently developing technology that helps lower costs, improve quality and enable faster, better delivery of healthcare services," said Rick Farnell, director of worldwide sales, Software Alliances and Channels, Sun Microsystems. "Sun Java CAPS will enable TechniScan to connect all of its systems to a central datacenter so it can provide integrated and quality healthcare services to operators, image reviewers, insurers and physicians through a Web-based architecture."

TechniScan's SVARA imaging system uses an enhanced data environment of digital communication and simulation that requires an advanced database to manage the volume of data and complex data relationships. Leveraging Sun Java CAPS, a component of the Java Enterprise System, TechniScan will seamlessly and securely connect all its breast-scanning solutions to a central datacenter. Sun Java CAPS will incorporate traditional master data management (MDM) functionality with functions for composite applications development in a SOA. It provides a comprehensive integration platform to build and manage TechniScan's applications that preserve the company's investments in existing applications while enhancing, aggregating and leveraging the patient data within them.

"In today's healthcare industry, the integration and sharing of appropriate patient health information is becoming an essential component of quality healthcare delivery," said David C. Robinson, chief executive officer at TechniScan, Inc. "We chose Sun because of its excellent reputation as a healthcare solution leader. Sun demonstrates the vision and visibility, as well as the technology, that will help TechniScan reach our goals and bring SVARA to market faster to help improve the future of women's health."

To further help with integration, Sun will also join with systems integrator LCN Technology, which will provide extensive consultant services and network experience to the project. As a premier Sun and SOA Speciality certified partner, LCN will work with TechniScan to define the requirements and solutions to best implement and capitalize on Sun technology including the Sun Blade T6340 Server Modules combined with the Sun Storage 7310 Unified Storage System to develop a state of the art storage platform, JavaFX for building rich Web applications and Sun's Electronic Master Patient Index (EMPI), for sharing patient data across organizations.

Sun has more than 20 years of experience working with hospitals, clinics and insurers around the world. It is one of the acknowledged leaders in the design, delivery and operation of large-scale healthcare IT systems, with implementations in the US, Australia, Canada, Germany, Singapore and the UK. In these and other countries, Sun's software, storage, systems and services help deliver secure health information exchange, data management compliance, and caregiver mobility solutions that reduce costs and medical errors, while improving efficiency and patient care.

About Sun Microsystems, Inc.
Sun Microsystems develops the technologies that power the global marketplace. Guided by a singular vision -- "The Network is the Computer" -- Sun drives network participation through shared innovation, community development and open source leadership. Sun can be found in more than 100 countries and on the Web at http://sun.com.

Sun, Sun Microsystems, the Sun logo, Java, Sun Ray, Solaris, Sun Blade and The Network Is The Computer are trademarks or registered trademarks of Sun Microsystems, Inc. or its subsidiaries in the United States and other countries.

Additional Links:

http://http://finance.yahoo.com/news/TechniScan-Inc-Selects-Sun-bw-2379315522.html?

Continue watch for entry point..now .84 may correct...

In Preparation for Commercialization of SVARA (TM) , TechniScan Appoints Joe Pepper, PhD to Board of Directors

- New Board Member has 20 years' experience managing medical device companies -
SALT LAKE CITY, Dec. 16 /PRNewswire-FirstCall/ -- TechniScan, Inc. (OTC Bulletin Board: TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, announced today that Joe Pepper, PhD, has been appointed to the TechniScan Board of Directors.

Board Chairman Ken Hungerford commented, "Joe has extensive experience running small to large medical devices companies, including GE OEC Medical and U-Systems, both of whom compete in the area of breast imaging. The TechniScan Board is excited to have Joe Pepper on the team and he has already made significant contributions to helping us bring TechniScan's SVARA (TM) Warm Bath Ultrasound closer to realization in the marketplace."

"Joe Pepper's outstanding educational background and expertise in the field of ultrasound breast imaging make him a perfect addition to our Board of Directors," added TechniScan CEO David C. Robinson. "His energy and enthusiasm for what we are trying to do with breast cancer detection is highly motivating, yet he knows how to ask the tough questions. He wants to make sure we have the best possible product and are aligning everything we do with the needs of the customer."

Since 2007, Joseph W. Pepper has served as a consultant to medical device start-ups. From 2003 until 2007, Dr. Pepper served as CEO of U-Systems, Inc., a privately backed start-up that developed automated ultrasound for the early detection of breast cancer in women with dense breast tissue. Dr. Pepper served as CEO for OEC Medical Systems, a NYSE-traded, mobile fluoroscopic imaging equipment manufacturer and seller, from 1997 until the sale of the company to GE Healthcare in 1999. Prior to joining OEC, Dr. Pepper spent 15 years with The BOC Group, Plc., where he served as president of Ohmeda Medical Devices, the healthcare subsidiary of BOC responsible for international selling and distribution of medical devices, and as president of Ohmeda Medical Equipment, which was responsible for Ohmeda's monitoring and anesthesia equipment business.

Dr. Pepper has a BS/MS in Engineering Science from Florida State University, a PhD in Mechanical Engineering from Stanford University and an MBA from The Harvard Business School.

Dr. Pepper commented, "I am excited about this opportunity to add my knowledge and perspective to TechniScan, a company I have admired for quite some time. The images I have seen have impressive specificity and have the potential to change the ways that radiologists and oncologists detect cancer in the breast." Pepper continued, "The TechniScan Board has outstanding depth and diversity of perspective. I am honored to be a part of the group and I feel confident that, with our collective experience, we can take TechniScan and help make its imaging modality the premier method for post-mammographic lesion detection for women."

TechniScan Announces Continued OEM Relationship with Esaote , Including Extension to OEM AgreementLast update: 12/10/2009 10:58:00 AM-- Esaote Signs Letter of Intent to Manufacture TechniScan SVARA(TM) System -- SALT LAKE CITY, Dec 10, 2009 (BUSINESS WIRE) -- TechniScan, Inc. (TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, announced today that Genoa, Italy-based Esaote has recently agreed to continue, and extend, its original equipment manufacturing (OEM) agreement with TechniScan. Esaote () -- a medical imaging company specializing in high performance ultrasound systems -- is one of the fastest growing ultrasound companies in the world today. The supplement to the OEM agreement provides for additional support from Esaote for TechniScan's engineering, regulatory and manufacturing initiatives. This support will provide TechniScan with the added resources to complete development of SVARA (TM) and enables TechniScan to focus on development of the TechniScan Imaging Network that allows physicians, patients and payers to safely and efficiently store and transmit image data and records across the network. TechniScan will also focus on sales and marketing while Esaote utilizes its proven manufacturing and regulatory support capabilities to produce the system in its CE-mark qualified manufacturing facility in Genoa, Italy. Esaote will be paid either common stock or cash for its services under the supplement to the OEM agreement, as determined by Esaote anytime during the second quarter of 2010. The parties also signed a non-binding Letter of Intent (LOI) that outlines the terms and approach for Esaote to partner with TechniScan to manufacture and source TechniScan's SVARA (TM) whole breast imaging system. The LOI also addresses Esaote's expectation of marketing and distributing SVARA (TM) under Esaote's own brand, and will pay a license fee to TechniScan calculated as a percentage of Esaote's revenue in Europe. TechniScan Chief Executive Officer David C. Robinson commented, "We are excited that Esaote continues to validate our product and approach by extending our OEM Agreement and we look forward to benefitting from Esaote's proven manufacturing capabilities. This continuation of our agreement further strengthens our partnership and confirms our approach to a global manufacturing and distribution strategy, and continues to validate our technology and partnership choice with Esaote, one of the industry's fastest growing medical imaging companies."

TechniScan Expands Operational Team to Accelerate Development and Commercialization of Breast Imaging Technology
CEO Dave Robinson Optimistic About the Future of Ultrasound Breast Imaging

SALT LAKE CITY--(BUSINESS WIRE)--TechniScan, Inc. (OTCBB: TSNI) (“TechniScan” or the “Company”), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, announced today that three new director-level positions had been filled along with the hiring of a senior software engineer.

“We were able to attract experienced and industry-respected senior personnel partly because the controversy surrounding mammography has heightened interest in ultrasound breast imaging technology, especially for use with women under 50,” stated Chief Executive Officer David C. Robinson. “One of the unique aspects about these people is that they are all senior-level executives who are still willing to roll up their sleeves and get the work done.”

TechniScan has hired Dr. John C. Klock, MD, as the Company’s Chief Medical Director; Andy Cier as Director of Marketing and Communications; Jessica Smith, MS, as Senior Regulatory and Market Development Manager; and Louis D. Langholtz as Senior Software Engineer.

Dr. Klock, Chief Medical Director, is a board-certified Internist and Hematologist-Oncologist who has been involved in the start-up of five medical companies. With more than 70 peer-reviewed medical and scientific publications and eight granted U.S. patents to his name, Dr. Klock will be developing TechniScan’s training and analytical protocols. He will also be working with Director of Clinical Affairs Karleen Callahan, with Jessica Smith in Regulatory Affairs and with clinical study sites to ensure that the Company’s clinical objectives are being met.

Mr. Cier, as Director of Marketing and Communications, is also a marketing consultant and former Partner, General Manager of the Salt Lake office of Riester, an advertising, marketing and PR firm. Mr. Cier will be overseeing the marketing and branding of SVARATM, the system that captures, computes and shares ultrasound images of the breast. He will also oversee TechniScan’s Investor Relations, Public Relations and Advertising functions for the commercial launch of SVARATM, estimated to take place in 2010.

Ms. Smith, Senior Regulatory and Market Development Manager, has a master’s in bioengineering and has worked in the medical industry in a variety of roles over the past 15 years, from regulatory affairs to medical writing and market research. Ms. Smith will oversee TechniScan’s 510k and other regulatory filings with the FDA, and she will be managing TechniScan’s regulatory consultant, the Anson Group.

As Senior Software Engineer, Mr. Langholtz has more than 20 years’ systems and applications level programming experience in 20-plus computer languages. His proven background in software programming, particularly with highly advanced embedded systems, will be of significant value in support of the system operation, image processing and application level programming for TechniScan’s products.

TechniScan Announces Hiring of New CFO
Steven K. Passey, Former CAO at Mrs. Fields Now in Charge of Financial Operations

SALT LAKE CITY--(BUSINESS WIRE)--TechniScan, Inc. (OTCBB:TSNI) (“TechniScan” or the “Company”), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that Steven K. Passey, CPA, has joined the Company as its new Chief Financial Officer. TechniScan, which recently became a publicly-traded company, conducted an extensive search of qualified candidates and found Mr. Passey’s background and qualifications lined up perfectly with the needs of a firm that is now publicly-owned.

“Steve is a fantastic addition to our roster of talented professionals,” Chief Executive Officer David C. Robinson commented. “His background with publicly-traded companies, IPOs, budget planning and cost control ensures we will maintain the highest standards as a public company. More importantly, Steve’s background will help us secure the additional investment we need to ensure our Svara™ automated, 3D ultrasound system is launched properly and is available to help doctors improve breast cancer detection and to ultimately save lives.”

TechniScan’s new CFO was most recently the Vice President, Chief Accounting Officer and Treasurer for Mrs. Fields’ Famous Brands (Mrs. Fields and TCBY brands) in Salt Lake City, UT. Prior to that, Mr. Passey was hired to spearhead all SEC filings for Extra Space Storage, another publicly-traded company based in Salt Lake. As Controller of REIT Properties for that $200M revenue company, he played a key role in helping launch 34 newly acquired properties. Previously, Mr. Passey also spent several years as a Senior Manager for public accounting firm Ernst & Young. Mr. Passey received his Bachelor of Science degree in accounting from the University of Utah, and is a certified public accountant.

Mr. Passey added, “I am excited to join TechniScan at this important point in the Company’s evolution. TechniScan’s automated, 3D ultrasound technology has the potential to be an important tool in the early and accurate detection of one of the leading killers among women. I look forward to contributing my experience and expertise to ensure a rapid launch of this technology and to help drive shareholder value.”

Up 8.49% (.09) to $1.15

Wife says Mammograms like Tit caught in wringer...
if this can replace that ... it seems that a less painful non-intrusive option would be very popular...